Advancing cell-based cancer immunotherapy through stem cell engineering

YR Li, ZS Dunn, Y Yu, M Li, P Wang, L Yang - Cell Stem Cell, 2023 - cell.com
Advances in cell-based therapy, particularly CAR-T cell therapy, have transformed the
treatment of hematological malignancies. Although an important step forward for the field …

Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy

M Chehelgerdi, F Behdarvand Dehkordi… - Molecular Cancer, 2023 - Springer
The advent of iPSCs has brought about a significant transformation in stem cell research,
opening up promising avenues for advancing cancer treatment. The formation of cancer is a …

Mucosal-associated invariant T cells for cancer immunotherapy

YR Li, K Zhou, M Wilson, A Kramer, Y Zhu, N Dawson… - Molecular Therapy, 2023 - cell.com
Human mucosal-associated invariant T (MAIT) cells are characterized by their expression of
an invariant TCR α chain Vα7. 2-Jα33/Jα20/Jα12 paired with a restricted TCR β chain. MAIT …

Unlocking the potential of allogeneic Vδ2 T cells for ovarian cancer therapy through CD16 biomarker selection and CAR/IL-15 engineering

D Lee, ZS Dunn, W Guo, CJ Rosenthal… - Nature …, 2023 - nature.com
Allogeneic Vγ9Vδ2 (Vδ2) T cells have emerged as attractive candidates for develo**
cancer therapy due to their established safety in allogeneic contexts and inherent tumor …

Targeting immunosuppressive tumor-associated macrophages using innate T cells for enhanced antitumor reactivity

YR Li, J Brown, Y Yu, D Lee, K Zhou, ZS Dunn, R Hon… - Cancers, 2022 - mdpi.com
Simple Summary This study seeks to evaluate innate T cells for antitumor therapies that can
target both tumor cells and immunosuppressive tumor-associated macrophages (TAMs) …

Target tumor microenvironment by innate T cells

YR Li, M Wilson, L Yang - Frontiers in Immunology, 2022 - frontiersin.org
The immunosuppressive tumor microenvironment (TME) remains one of the most prevailing
barriers obstructing the implementation of effective immunotherapy against solid-state …

Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers

YR Li, S Zeng, ZS Dunn, Y Zhou, Z Li, J Yu, YC Wang… - Iscience, 2022 - cell.com
Allo-HSCT is a curative therapy for hematologic malignancies owing to GvL effect mediated
by alloreactive T cells; however, the same T cells also mediate GvHD, a severe side effect …

Tumor-localized administration of α-GalCer to recruit invariant natural killer T cells and enhance their antitumor activity against solid tumors

YR Li, Y Zhou, M Wilson, A Kramer, R Hon… - International Journal of …, 2022 - mdpi.com
Invariant natural killer T (iNKT) cells have the capacity to mount potent anti-tumor reactivity
and have therefore become a focus in the development of cell-based immunotherapy. iNKT …

[HTML][HTML] Unveiling the potential of gene editing techniques in revolutionizing cancer treatment: A comprehensive overview

P Garg, G Singhal, S Pareek, P Kulkarni… - … et Biophysica Acta (BBA …, 2024 - Elsevier
Gene editing techniques have emerged as powerful tools in biomedical research, offering
precise manipulation of genetic material with the potential to revolutionize cancer treatment …

[HTML][HTML] Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment

Y Chang, M Chang, X Bao, C Dong - Bioactive materials, 2024 - Elsevier
Adoptive immunotherapy, notably involving chimeric antigen receptor (CAR)-T cells, has
obtained Food and Drug Administration (FDA) approval as a treatment for various …